Skip to main content
. Author manuscript; available in PMC: 2013 Nov 19.
Published in final edited form as: Pharmacoeconomics. 2011 Jul;29(7):10.2165/11586120-000000000-00000. doi: 10.2165/11586120-000000000-00000

Table IV.

Base Case and Sensitivity Analysis: Delivery Unit Cost (USD 2009) of ART per patient per year, by country income level

Low income Lower middle income Upper middle income All

Base case Mean 839 1,246 2,783 1,494
Median 792 932 1,454 1,005
SD 175 1,546 2,500 1,628
Min 682 156 1,230 156
Max 1,089 3,904 5,667 5,667
Countries 4 5 3 12
Studies (N) 6 7 13 26
Data points/sites (n) 10 12 24 45

1. Weighing all study sites, instead of all countries equally Mean 770 714 2,366 1,600
Median 797 298 1,397 1,077
SD 226 1,067 2 1,772
Min 263 97 522 97
Max 1,089 3,904 7,688 7,688
Countries 4 5 3 12
Studies (N) 6 7 13 26
Data points/sites (n) 10 12 24 46

2. Adding studies reporting total unit cost without ARV/lab/HR break-down Mean 713 1,314 Unchanged from base-case 1,422
Median 773 932 932
SD 319 1,637 1,639
Min 211 162 162
Max 1,089 4,212 5,667
Countries 5 5 13
Studies (N) 7 9 29
Data points/sites (n) 11 14 48

3. Country income level according to costing year Mean 565 1,683 3,068 1,496
Median 646 1,454 1,241 1,073
SD 346 886 2,537 1,559
Min 97 522 1,068 156
Max 1,089 3,904 7,688 5,667
Countries 7 4 2 12
Studies (N) 11 9 6 26
Data points/sites (n) 20 13 13 45

Notes: The base case aggregates total ART unit costs per person per year (in 2009 USD) by first taking the median within each country. Sensitivity analyses are as follows: 1. All study sites weighted equally, regardless of country or number of sites per country. 2) Expanded dataset to include studies which did not include a break-down of cost components, but had data on total ART costs. 3) Use World Bank GNI per capita data at the time of the study costing, instead of 2009 GNI, to classify countries according to income level. Baseline estimates based on more than 14,765 patients from 26 studies, plus additional studies that did not disaggregate costs by cost component. Twelve studies specifically reported costs for first-line treatment; one study [39] specifically included second-line treatment but those specific costs were excluded. Total data points aggregate to 45 because two studies from Mexico [37, 38] were considered as only one data point as they referred to the same study population, but we needed both sources to obtain all the necessary information. See tables I, II, and III, text and annexes for further details.